Effects of Ougan juice on P450 activities using a cocktail method

Pharmazie

Volumn 67, Issue 3, 2012, Pages 242-246

  Lin, Guan Yang ^a   Ma, Jian She ^a   Xu, Ren Ai ^a   Hu, Lu Feng ^a   Wang, Zhe ^a   Wang, Xian Qin ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CITRUS FRUIT EXTRACT; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; OMEPRAZOLE; OUGAN EXTRACT; PHENACETIN; TOLBUTAMIDE; UNCLASSIFIED DRUG; DRUG; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; ISOENZYME;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CITRUS FRUIT; CITRUS SUAVISSIMA HORT. EX TANAKA; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; FRUIT JUICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MULTIPLE CYCLE TREATMENT; NONHUMAN; RAT; SINGLE DRUG DOSE; ANIMAL; BEVERAGE; CALIBRATION; CHEMISTRY; CITRUS; FOOD DRUG INTERACTION; HALF LIFE TIME; LIMIT OF DETECTION; METABOLISM; REGRESSION ANALYSIS; STANDARD; WISTAR RAT;

ANIMALS; AREA UNDER CURVE; BEVERAGES; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITRUS; CYTOCHROME P-450 ENZYME SYSTEM; FOOD-DRUG INTERACTIONS; HALF-LIFE; INDICATORS AND REAGENTS; ISOENZYMES; LIMIT OF DETECTION; MALE; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; RATS; RATS, WISTAR; REFERENCE STANDARDS; REGRESSION ANALYSIS;

EID: 84861157721     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.1056     Document Type: Article

References (30)

1. Bruce MA, Hall SD, Haehner-Daniels BD, Gorski JC (2001) In vivo effect of clarithromycin on multiple cytochrome P450 s. Drug Metab Dispos 29: 1023-1028.
2. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS, Jr. (2003) Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase- 2, and xanthine oxidase activities with the "Cooperstown 5 + 1 cocktail". Clin Pharmacol Ther 74: 437-447.
3. Chang GW, Kam PC (1999) The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia 54: 42-50.
4. Chen X, Yuan K, Si J (2009) Analysis of constituents of metal elements and amino acids in new cultivar Citrus reticulata Blanco cv. Ougan fruit from China. Int J Food Sci Nutr 60 Suppl 7: 116-127.
5. Chow HH, Hakim IA, Vining DR, Crowell JA, Cordova CA, Chew WM, Xu MJ, Hsu CH, Ranger-Moore J, Alberts DS (2006) Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev 15: 2473-2476.
6. Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yasar U, Bertilsson L (2003) The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 73: 517-528.
7. Eaton DL, Gallagher EP, Bammler TK, Kunze KL (1995) Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5: 259-274.
8. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA (1997) Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 62: 365-376.
9. Gao ZW, Shi XJ, Yu C, Li SJ, Zhong MK (2007) Simultaneous determination of the inhibitory potency of compounds on the activity of five cytochrome P-450 enzymes using a cocktail probe substrates method. Yao Xue Xue Bao 42: 589-594.
10. Krosser S, Neugebauer R, Dolgos H, Fluck M, Rost KL, Kovar A (2006) Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial. Eur J Clin Pharmacol 62: 277-284.
11. Lin XR, Xu JG (2007) The investigation of Citrus reticulata Blanco cv. Ougan history. The fruit trees in Southern China 134: 22-23.
12. Liu Y, Jiao J, Zhang C, Lou J (2009) A simplified method to determine five cytochrome p450 probe drugs by HPLC in a single run. Biol Pharm Bull 32: 717-720.
13. Nebert DW, Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360: 1155-1162.
14. Rendic S, Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29: 413-580.
15. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57: 465-480.
16. Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ, Shin JG (2007) Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther 82: 531-540.
17. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423.
18. Smith D, Sadagopan N, Zientek M, Reddy A, Cohen L (2007) Analytical approaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery. J Chromatogr B Analyt Technol Biomed Life Sci 850: 455-463.
19. Streetman DS, Bertino JS, Jr., Nafziger AN (2000a) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10: 187-216.
20. Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS, Jr. (2000b) Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther 68: 375-383.
21. Tanaka E, Kurata N, Yasuhara H (2003) How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? J Clin Pharm Ther 28: 157-165.
22. Tang H, Min G, Ge B, Li Y, Liu X, Jiang S (2008) Evaluation of protective effects of Chi-Zhi-Huang decoction on Phase I drug metabolism of liver injured rats by cocktail probe drugs. J Ethnopharmacol 117: 420-426.
23. Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, Skott A, Sorgel F, Klaassen T, Kasel D, Harlfinger S, Doroshyenko O, Frank D, Kirchheiner J, Brater M, Richter K, Gramatte T, Fuhr U (2005) Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos 33: 1859-1866.
24. Yao YM, Cao W, Cao YJ, Cheng ZN, Ou-Yang DS, Liu ZQ, Zhou HH (2007) Effect of sinomenine on human cytochrome P450 activity. Clin Chim Acta 379: 113-118.
25. Yin OQ, Lam SS, Lo CM, Chow MS (2004) Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies. Rapid Commun Mass Spectrom 18: 2921-2933.
26. Zhang LL, Zhang JR, Guo K, Ji H, Zhang Y, Jiang SX (2011) Effects of fluoroquinolones on CYP4501A and 3A in male broilers. Res Vet Sci 90: 99-105.
27. Zhang S, Song N, Li Q, FanH, Liu C (2008) Liquid chromatography/tandem mass spectrometry method for simultaneous evaluation of activities of five cytochrome P450s using a five-drug cocktail and application to cytochrome P450 phenotyping studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci 871: 78-89.
28. Zhou SF, Liu JP, Chowbay B (2009a) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41: 89-295.
29. Zhou SF, Liu JP, Lai XS (2009b) Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem 16: 2661-2805.
30. Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N, Zhou HH (2001) Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther 70: 455-461.